| (Values in U.S. Thousands) | Mar, 2023 | Dec, 2022 | Jun, 2022 | Mar, 2022 | Dec, 2021 |
| Sales | 254 | 351 | 1,202 | 1,237 | 5,604 |
| Sales Growth | -27.64% | -70.80% | -2.83% | -77.93% | +9,398.31% |
| Net Income | -3,546 | -3,845 | -7,880 | -4,608 | -2,602 |
| Net Income Growth | +7.78% | +51.21% | -71.01% | -77.09% | +24.21% |
Sqi Diagnostics Inc (SQD.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
SQI Diagnostics Inc is the leader in the field of lung health. The company develops and manufactures respiratory health and precision medicine tests that run on SQI's automated systems. The company is developing tests to simplify and improve COVID-19 antibody monitoring, rapid acute lung injury testing, donor organ transplant informatics, and immunological protein and antibody testing. Its geographical segments are the United States, Canada, and Europe. Canada accounts for more than half of its revenues.